Aditxt, Inc. filings document the company’s life sciences platform, its common stock capital structure, and material events affecting its operating subsidiaries and public-company status. Recent Form 8-K reports cover the completed acquisition of Ignite Proteomics, related financial statements and pro forma information, senior unsecured promissory notes, at-the-market offering capacity, and Nasdaq listing-compliance matters.
Proxy materials and meeting reports describe board elections, auditor ratification, executive-compensation votes, reverse stock split authority, and other stockholder matters. The filing record also includes disclosures on preferred stock issued in acquisition consideration, equity financing arrangements, governance approvals, and risks associated with maintaining exchange listing standards.
HRT Financial LP has filed an initial ownership report for Aditxt, Inc. The Form 3 shows HRT Financial as a ten percent owner, directly holding 133,574 Class A Shares following the reported date. The filing records this ownership position rather than any new share purchase or sale.
Aditxt, Inc. entered into a financing deal by issuing and selling senior unsecured promissory notes with an aggregate original principal amount of $1,250,000 to accredited investors for a purchase price of $1,000,000, reflecting a $250,000 original issue discount. The Notes bear 10% annual interest, payable monthly, and are scheduled to mature on September 30, 2026. If Aditxt sells common stock through an at-the-market offering or equity line of credit, all such gross proceeds, net of specified expenses, must be used weekly to redeem the Notes at 120% of the amount redeemed. Upon an event of default, holders can require redemption at 125% of the redeemed amount, and a bankruptcy event triggers immediate payment of 125% of all outstanding principal, interest and late charges, alongside restrictive covenants after maturity.
Aditxt, Inc. registers up to 148,278,241 shares of Common Stock for resale by selling stockholders, representing shares issuable upon exercise of outstanding warrants. The registration covers resale on a resale basis by the identified selling holders.
The Company will not receive proceeds from secondary sales; however, if the warrants are exercised for cash at the current $0.50 exercise price, cash proceeds to the Company would be approximately $74.14 million. The prospectus states the company’s Nasdaq closing price on April 2, 2026 was $0.794 per share.
Aditxt, Inc. filed an amended current report to add full financial statements for its acquisition of Ignite Proteomics LLC and related unaudited pro forma consolidated financials. The deal consideration includes 36,000 shares of Series A-2 Convertible Preferred Stock with an aggregate stated value of $36.0 million.
Ignite’s audited results show modest 2025 revenue of $43,539 and a net loss of $5,701,059, leading to a member’s deficit of $6,807,109 and a going concern warning due to recurring losses and negative operating cash flows. Pro forma balance sheets record preliminary goodwill of $36,551 (in thousands of dollars) related to the transaction.
Aditxt, Inc. is calling a virtual 2026 annual meeting on May 1, 2026 at 12:00 p.m. ET, where holders of common stock as of the March 26, 2026 record date, when 861,482 shares were outstanding, can vote online.
Stockholders will vote on six items: electing five directors for one-year terms; ratifying dbbmckennon as independent auditor for 2026; an advisory “say‑on‑pay” vote on executive compensation; an advisory vote on how often to hold say‑on‑pay, with the board recommending every three years; authorizing the board to implement a reverse stock split within one year at a ratio between 1‑for‑2 and 1‑for‑250; and approving the ability to adjourn the meeting if needed.
The proxy details leadership and compensation, including 2025 base salaries of $500,000 for CEO Amro Albanna, $325,000 for Chief Innovation Officer Shahrokh Shabahang, $385,008 for Chief M&A Officer Corinne Pankovcin, and $395,000 for CFO Thomas Farley, plus change‑in‑control severance protections. It also confirms independent board committees, audit fees, and that the reverse split is intended to support Nasdaq listing and broaden investor appeal.
Aditxt, Inc. reports that Nasdaq has determined the company is back in compliance with its continued listing standards under Nasdaq Listing Rule 5550(b)(1). This decision is based on Aditxt’s Form 10-K, which shows stockholders’ equity of $3,953,682, and Nasdaq has closed the matter.
Aditxt, Inc. files its annual report describing a multi-subsidiary biotech platform focused on immune modulation, molecular diagnostics and infectious disease therapeutics, all still in development with no significant commercial revenue. The company reports a net loss of $42,787,043 for 2025 and an accumulated deficit of $209,808,770, raising substantial doubt about its ability to continue as a going concern.
Aditxt highlights Adimune’s ADI-100 immune tolerance candidate moving toward first-in-human trials, Pearsanta’s Mitomic-based cancer and endometriosis tests in development, and newer platforms in antiviral (Adivir) and women’s health (Adifem). The company outlines the now-terminated Evofem merger after multiple amendments, while retaining its Evofem preferred shares and warrants.
The report flags serious Nasdaq listing risks. As of March 30, 2026, Aditxt’s market capitalization is about $713,000, far below both existing equity thresholds and a proposed $5.0M market cap standard that, if adopted, could trigger rapid suspension and delisting without a cure period. Aditxt states its current cash will not fund 12 months of operations and that it must raise additional capital, with uncertainty around availability and terms.
Aditxt, Inc. increased the maximum aggregate offering price of its at-the-market common stock program to $53,398,964 under its Sales Agreement with H.C. Wainwright & Co.
This includes an additional $36,800,000 of capacity, on top of approximately $21,257,000 of common stock already sold under the agreement, and is supported by a new prospectus supplement and related legal opinion filed as an exhibit.
ADTX amends its shelf to increase its ATM capacity to $53,398,964. This prospectus supplement adds $36,800,000 of new ATM capacity, bringing the aggregate authorized amount under the sales agreement to $53,398,964, and leaves prior terms and the sales agreement unchanged.
The supplement states the company has previously sold approximately 398,950 shares for aggregate gross proceeds of $21,257,000, leaving about $16,500,000 of prior capacity before this increase. The filing also discloses the last reported Nasdaq sale price of the common stock was $0.81 per share as of March 27, 2026.